Literature DB >> 6538658

Frequent neurologic toxicity associated with amiodarone therapy.

M E Charness, F Morady, M M Scheinman.   

Abstract

Fifty-four consecutive patients were treated with amiodarone for symptomatic ventricular tachycardia or ventricular fibrillation refractory to treatment with conventional antiarrhythmic drugs. A reversible neurologic syndrome of tremor, ataxia, and occasionally peripheral neuropathy without nystagmus, dizziness, encephalopathy, or long-tract signs developed in 54% of the patients and was the most common reason for altering or discontinuing drug therapy. Neurologic side effects improved or resolved within 2 days to 4 weeks of decreasing or discontinuing amiodarone. Frequent neurologic toxicity is a hitherto undescribed complication of amiodarone therapy. Wider recognition of this syndrome will avoid unnecessary and costly diagnostic evaluation.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6538658     DOI: 10.1212/wnl.34.5.669

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  17 in total

Review 1.  Drug-induced cerebellar ataxia: a systematic review.

Authors:  J van Gaalen; F G Kerstens; R P P W M Maas; L Härmark; B P C van de Warrenburg
Journal:  CNS Drugs       Date:  2014-12       Impact factor: 5.749

Review 2.  Amiodarone-associated optic neuropathy: a critical review.

Authors:  Rod S Passman; Charles L Bennett; Joseph M Purpura; Rashmi Kapur; Lenworth N Johnson; Dennis W Raisch; Dennis P West; Beatrice J Edwards; Steven M Belknap; Dustin B Liebling; Mathew J Fisher; Athena T Samaras; Lisa-Gaye A Jones; Katrina-Marie E Tulas; June M McKoy
Journal:  Am J Med       Date:  2012-03-03       Impact factor: 4.965

Review 3.  Amiodarone-Associated Optic Neuropathy: Clinical Review.

Authors:  An-Guor Wang; Hui-Chen Cheng
Journal:  Neuroophthalmology       Date:  2016-11-18

Review 4.  Neurologic Complications of Commonly Used Drugs in the Hospital Setting.

Authors:  Elliot T Dawson; Sara E Hocker
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

5.  Sotalol versus Amiodarone in Treatment of Atrial Fibrillation.

Authors:  John Somberg; Janos Molnar
Journal:  J Atr Fibrillation       Date:  2016-02-29

6.  A Physiologically Based Pharmacokinetic Model of Amiodarone and its Metabolite Desethylamiodarone in Rats: Pooled Analysis of Published Data.

Authors:  Jing-Tao Lu; Ying Cai; Feng Chen; Wei-Wei Jia; Zhe-Yi Hu; Yuan-Sheng Zhao
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-12       Impact factor: 2.441

7.  Long-term amiodarone therapy raises serum cholesterol.

Authors:  A A Lakhdar; E Farish; W S Hillis; F G Dunn
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

8.  Antiarrhythmic drugs and polyneuropathy. The Collaborative Group for the Study of Polyneuropathy.

Authors: 
Journal:  J Neurol Neurosurg Psychiatry       Date:  1994-03       Impact factor: 10.154

9.  Side effects with amiodarone therapy.

Authors:  R Shukla; N I Jowett; D R Thompson; J E Pohl
Journal:  Postgrad Med J       Date:  1994-07       Impact factor: 2.401

10.  Myopathy during amiodarone treatment: a case report.

Authors:  F Carella; E Riva; L Morandi; E Cappiello; A Mangoni
Journal:  Ital J Neurol Sci       Date:  1987-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.